Taxotere® (T) and doxorubicin (D) combination:: A phase II South American study in first line treatment (tt) of metastatic breast cancer (MBC)

被引：2
|
作者：
Vallejos, C
Nunez, P
Orlandi, L
Carranza, H
Fodor, M
Reyes, JM
Majlis, A
Gavilanes, P
Boussard, B
Salas, E
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81740-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1324
引用
收藏
页码：S329 / S329
页数：1
相关论文
共 50 条
  • [21] Phase II trial biweekly paclitaxel (P), doxorubicin (D) and Gemcitabine (G) as first line chemotherapy for metastatic breast cancer (MBC): Preliminary results
    Lozano, A
    Sanchez-Rovira, P
    Medina, B
    Gonzalez, E
    Mohedano, N
    Jaen, A
    Porras, I
    Fernandez, M
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 18 - 18
  • [22] Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer
    Alexopoulos, A
    Karamouzis, MV
    Stavrinides, H
    Ardavanis, A
    Kandilis, K
    Stavrakakis, J
    Georganta, C
    Rigatos, G
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (06) : 891 - 895
  • [23] A combination of vinorelbine and carboplatin as first line treatment for patients with metastatic breast cancer - A phase II study.
    Protheroe, AS
    Rodwell, S
    Aram, H
    Dodwell, D
    Crawford, M
    Bradley, C
    Perren, TJ
    Hill, S
    Joffe, JK
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 : 50 - 50
  • [24] Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.
    Fulfaro, F
    Valerio, MR
    Badalamenti, G
    Arcara, C
    Cicero, G
    Intrivici, C
    Crosta, A
    Sciortino, C
    Russo, A
    Gebbia, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 53S - 53S
  • [25] Docetaxel with epirubicin as first line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II study
    Morales, S
    Lorenzo, A
    Ramos, M
    Ballesteros, P
    Méndez, M
    Almanza, C
    Moreno-Nogueira, J
    Casal, J
    Castellanos, J
    Lizón, J
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [26] Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC): The CAT regimen.
    Guastalla, JP
    Hardy-Bessard, AC
    Geay, JF
    Cure, H
    Ray-Coquard, I
    Paraiso, D
    Pujade-Lauraine, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 81S - 81S
  • [27] A phase II study of TLC D-99 (liposome encapsulated doxorubicin), in combination with (5-FU) and cyclophosphamide (CPA) in the treatment of metastatic breast cancer (MBC)
    Valero, V
    Azarnia, N
    Buzdar, A
    Theriaulst, R
    Willey, J
    Lee, L
    Hortobagyi, G
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 14 - 14
  • [28] First line chemotherapy with paclitaxel (P) and mitoxantrone (M) metastatic breast cancer (MBC). A phase II study
    Tsavdaridis, D
    Athanassiadis, A
    Kourtidou, P
    Hatzikonstantinou, N
    Saleh, M
    Hatzichristou, A
    Karapanagiotis, K
    Moschidis, A
    Liaros, A
    Apostolidis, A
    Harmouziadis, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S325 - S326
  • [29] EVALUATION OF TRILOSTANE (T) IN TREATMENT OF METASTATIC BREAST-CANCER (MBC)-A PHASE-II STUDY
    BUZDAR, AU
    HORTOBAGYI, GN
    MARCUS, CE
    HOLMES, FA
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 218 - 218
  • [30] First-line chemotherapy of advanced or metastatic breast cancer (MBC) with docetaxel and doxorubicin in Indonesia: results from A phase II trial
    Abdulmuthalib
    Darwis, Idral
    Prayogo, Nugroho
    Sutjipto
    [J]. MEDICAL JOURNAL OF INDONESIA, 2005, 14 (01) : 20 - 25
12345